Key result
Increasing proportions of time on heparin with an APTT ≥0.2 anti-X(a) U/mL and on warfarin with an INR ≥2.0 were associated with significant reductions in 180-day VTE recurrence.
Why the study?
Does the intensity of heparin and warfarin anticoagulation predict 180-day VTE recurrence in patients with incident VTE?
Cohort (n=1,166)
No
Does the intensity of heparin and warfarin anticoagulation predict 180-day VTE recurrence in patients with incident VTE?
Maintaining adequate anticoagulation intensity with heparin (APTT ≥ 0.2 anti-X(a) U/mL) and warfarin (INR ≥ 2.0) significantly reduces the risk of 180-day VTE recurrence.
Answers are grounded in this paper and cite their sources.
Supports monitoring anticoagulation intensity in VTE; leaves open whether randomized trials confirm causality and guide practice.
To test recommended anticoagulation measures as predictors of 180-day venous thromboembolism (VTE) recurrence, we identified all Olmsted County, MN residents with incident VTE over the 14-year period of 1984-1997, and followed each case (N = 1166) forward in time for VTE recurrence. We tested the activated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures of heparin and warfarin anticoagulation as predictors of VTE recurrence while controlling for baseline and time-dependent characteristics using Cox proportional hazards modeling. Overall, 1026 (88%) and 989 (85%) patients received heparin and warfarin, respectively, and 85 (8%) developed VTE recurrence. In multivariable analyses, increasing proportions of time on heparin with an APTT ≥ 0.2 anti-X(a) U/mL and on warfarin with an INR ≥ 2.0 were associated with significant reductions in VTE recurrence, while the hazard with active cancer was significantly increased. Time from VTE onset to heparin start, duration of overlapping heparin and warfarin, and inferior vena cava (IVC) filter placement were not independent predictors of recurrence. At a heparin dose ≥ 30 000 U/d, the median proportion of time with an APTT ≥ 0.2 anti-X(a) U/mL was 92%, suggesting that routine APTT monitoring and heparin dose adjustment may be unnecessary. In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence.
No takes yet. Share an insight, caveat, or question.
Heit et al. (2011) conducted a cohort in Incident venous thromboembolism (deep vein thrombosis or pulmonary embolism) (n=1,166). Heparin and warfarin anticoagulation was evaluated on 180-day venous thromboembolism (VTE) recurrence. Increasing proportions of time on heparin with an APTT ≥0.2 anti-X(a) U/mL and on warfarin with an INR ≥2.0 were associated with significant reductions in 180-day VTE recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: